PURPOSE We wanted to describe how primary care clinicians care for patients with type 2 diabetes.
INTRODUCTION
I n 2002, visits to primary care physicians accounted for 62.7% of all offi ce visits in the United States, and diabetes mellitus ranked third, accounting for 3.1% of illness-related diagnoses. 1 Patients with type 2 diabetes often have acute or chronic comorbid health problems that force the clinician to prioritize and address the most pressing or symptomatic problems fi rst. [2] [3] [4] [5] [6] The situation is further complicated by the lack of access to a complete multidisciplinary diabetes health care team or by the lack of systems within primary care practices to provide ongoing support for this chronic disease. 7 In this article we describe the care provided by primary care clinicians to their patients who have type 2 diabetes using data from 3 sources: reports from physicians on their training and the patient care strategies they use to treat diabetes; surveys of patients about their diabetes care; and medical record reviews to determine medications used for diabetes and cardiovascular risk factor control, indicators of glycemic control, and diabetes-related com-TYPE 2 DIABETES MANAGEMENT plications. Our purpose was to describe the processes and outcomes of care of type 2 diabetes achieved by clinicians and their patients in member practices from 4 practice-based research networks (PBRNs). In particular, we examined practice design strategies for diabetes care, the composition of the health care team, the complexity of the health problems experienced by patients with type 2 diabetes (including comorbid conditions), control of diabetes (including cardiovascular risk-factor control), and the spectrum of treatment provided by their clinicians.
METHODS Settings
The Diabetes Outcome Study was conducted in 4 primary care PBRNs in the United States from February 2001 to April 2002. PBRNs are collaboratives of physicians or clinics committed to performing research of importance and relevance to their clinical practice. [8] [9] [10] [11] The American Academy of Family Physicians National Research Network (AAFP-NRN), the Minnesota Academy of Family Physicians Research Network (MAFPRN), the Texas Academy of Family Physicians Research Network (TAFP R-Net), and the Southern Primary Care Urban Research Network (SPUR-Net) each recruited constituent members for the study. The AAFP-NRN is a nationally distributed network of primary care physicians. The MAFPRN and TAFP R-Net are statewide networks administered through their respective state AAFP chapters, and SPUR-Net is a partnership of primary health-care organizations located in Houston, Texas.
Procedures
For this study, the term primary care clinician is used to include family physicians, general practitioners, general internists, and nurse-practitioners. Recruitment of clinicians began in July 2000.
Participating clinicians and study coordinators were instructed to enroll 10 consecutive patients who met the eligibility criteria for the study. Patients were considered eligible if they (1) had a current diagnosis of type 2 diabetes (based on clinician judgment), (2) were at least 18 years of age, (3) were seeing their primary care clinician at the study visit, (4) had visited the study clinic at least once within past 2 years, and (5) were able to speak and read English. The institutional review boards of Baylor College of Medicine and the University of Minnesota approved the study.
Measures
Clinicians completed a self-administered questionnaire at the initiation of the study. This instrument included demographic characteristics of the clinician (age, sex, years in practice) and the practice (eg, location, specialty, number of patients with diabetes seen in a typical month, specifi c practice management tools). 12 After giving consent to participate in the study and before their outpatient clinic visit with the clinician, patients completed a self-administered questionnaire that solicited general demographic information and specifi c information about self-management of diabetes.
After the offi ce visit, the study clinician or study coordinator completed a checklist of diabetes-related complications and clinical information from the patient' s medical record, as well as the most recent laboratory values for glycosylated hemoglobin (HbA 1c) and low-density lipoprotein cholesterol (LDL-C). Diabetes and cardiovascular risk-reduction medications were also abstracted.
Control Targets
The clinical indicators used were those defi ned by the Diabetes Quality Improvement Project from the National Committee for Quality Assurance (NCQA). 13 The HbA 1c level was used as the primary indicator of diabetes control; a value <7% indicated controlled, a value from 7.0% to 7.9% indicated intermediate control, and a value *8% indicated uncontrolled. These categories correspond to the 2002 clinical practice recommendations from the American Diabetes Association (ADA) 14 and were used by Parnes et al 15 to classify action levels for HbA 1c . Similarly, blood pressure was considered to be uncontrolled if *130/85 mm Hg and further defi ned using the Joint National Committee 7 (JNC 7) categorizations. 16 Finally, a LDL-C level of *100 mg/dL was considered uncontrolled. 16 
Data Analysis
We report descriptive characterizations of the 95 eligible clinicians and their patients, and the numbers of patients meeting the control targets for HbA 1c , blood pressure, and LDL-C. Contingency tables were used to express the relations between the control of HbA 1c, cardiovascular risk factors, and treatment strategies. Analyses were performed with SAS Versions 8.2 and 9.1.
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To determine whether diabetes and cardiovascular outcomes were associated with patient characteristics, clinician characteristics, practice design strategies, or treatment, general linear mixed models (multilevel models) were used for continuous HbA 1c levels. Generalized linear mixed models with HbA 1c , blood pressure, and LDL-C lipid control (controlled or not controlled) as the outcome (logit link) were used to extend the traditional logistic regression model to accommodate the multilevel structure and clustering of patients within physicians (Proc MIXED with GLIMMIX macro). 18 Variance components were examined at each level to determine whether random effects should be retained at that level (physician/practice). To enhance stability of the models, we used a model-building approach that involved determining which patient-level covariates were needed based on clinical or statistical signifi cance (at P <.15), and then we added level-2 predictors (physician/practice) one at a time. We also calculated the intraclass correlation coeffi cient for each control variable across the 95 clinicians.
RESULTS

Clinician and Patient Characteristics
A total of 141 clinicians volunteered to participate in the study. Of this number, 127 were family physicians, 2 were general practitioners, 5 were general internists, 4 identifi ed themselves as some combination thereof, and 3 were nurse-practitioners. Nine participants practiced in Canada, and 132 practiced in the United States.
Fourteen (10%) initial clinician volunteers withdrew before subject recruitment began, and 28 (20%) were unable to enroll any patients during the 15-month data-collection phase of the study. Of the remaining 99 clinicians, 4 were dropped from the analysis because they enrolled only 1 patient each.
The 95 participating clinicians had an average age of 45.7 years (SD, 7.8), and most (71.6%) were male. They had been in practice an average of 14.6 years (SD, 8.8) . The average number of adult patients with diabetes seen by each clinician in a typical month was 32.6, with 21.2% of clinicians providing care to more than 40 adult patients with diabetes per month. Practice type varied widely, with 36.8% of clinicians working in single-specialty groups, 19.0% in academic settings, 15.8% in multispecialty groups, 14.7% in solo practice, and 13.7% in a combination of settings. Practice location also varied widely; 37.9% of practices were in large cities with populations of more than 250,000, whereas 21.1% were in rural areas.
When clinicians who enrolled at least 2 patients (n = 95) were compared with those who enrolled none or 1 patient (n = 46), the 2 groups differed statistically on 4 (6.3%) of 63 survey items: (1) use of patient-held mini-records (25% vs 48%, P <.01); (2) use of letters or postcards (6% vs 39%, P <.01); (3) use of patient registries (8% vs 23%, P <.02; and (4) mean number of adult patients with diabetes seen per month (33 vs 44, P = .04).
For the 92 physicians who enrolled 2 or more patients, their demographic data were compared with data from the AAFP Masterfi le of active US members (32,219) reporting time in direct patient care as of February 2001 (the start of patient enrollment and data collection, this comparison does not include the 3 nurse-practitioners). Of the 6 demographic factors on which these comparisons were possible, the 92 study physicians did not differ statistically (P >.05) by sex, practice type, age, and years since medical school. The comparisons were statistically different (P <.05) for percentage of patients on Medicaid, with means of 11.5% (AAFP) and 15.2% (study), and for years in practice, with means of 11.3 years (AAFP) and 14.9 years (study), although for the study physicians this variable was measured as "years since residency."
Of the 834 patients who were enrolled in the study, only 822 patients were included in the analysis. Of the 12 that were dropped, 4 were the only patients their clinicians enrolled and 8 had a missing patient questionnaire or visit monitoring form. The characteristics of the 822 adult patients who were included in the analysis are given in Table 1 . Table 2 displays the diabetes-related complications and other comorbid health problems reported by patients in the study. Nearly one half (47.5%) of the patients reported having had at least 1 diabetes-related complication, with coronary artery disease, neuropathy, and nephropathy the most common. 
Comorbid Health Problems
Clinical Measures of Diabetes and Control Targets
Treatment
Treatment data were obtained from the visit monitoring form. Table 4 reports the specifi c diabetes and cardiovascular medications or classes of medications that the patients used. Nearly 3 in 4 patients were taking antihypertensive medications. More than one half were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and about one third were taking aspirin. More than one half were taking a lipid-lowering medication. Table 5 shows the relationship between HbA 1c level and the diabetes treatment strategies, including oral medications and insulin. Overall, 88.7% of patients were being treated with oral medications and/or insulin. The use of oral medications and insulin was more common among patients with HbA 1c levels ranging from 7% to 8% than among patients whose levels were <7%.
Among patients with HbA 1c levels >8%, 97.4% were treated with oral medications and/or insulin, and nearly one half (47.8%) were treated with at least 2 oral medications. Slightly more than one third (34.2%) of these patients were taking insulin.
To control cardiovascular risk factors (Table 6 ), 74.6% of patients were given prescriptions for an antihypertensive medication. There were 117 patients (14.5% of the total) who had poor blood pressure control and were receiving lifestyle change management only or no active treatment. There were 166 patients (24.7% of the total) with elevated LDL-C levels who received only lifestyle change management or no active treatment. Note: The data are expressed as frequencies and percentages (in parentheses); percentages in "Row Totals" are row percentages and in "Column totals" are column percentages. Sample size is 772 and excludes 50 cases with missing HbA1c values. Data are from visit monitoring form.
Factors
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models and models predicting poor control were generally similar. Few patient-level variables were associated with poor control of blood pressure or LDL-C. Older patients and those with less than a high school education were more likely to have poor control of blood pressure. African American patients were more likely to have poor LDL-C control than white patients. The only signifi cant clinician characteristic related to poor control of blood pressure was solo practitioner compared with single-specialty groups. No clinician characteristics were associated with control of LDL-C. Finally, none of the practice design features or treatment were associated with control of blood pressure or LDL-C.
DISCUSSION
We believe this cross-sectional study is the fi rst published that describes how primary care clinicians (mostly family physician members of PBRNs) from across the United States manage patients with type 2 diabetes and some of the results that are achieved. Our study found that these patients have moderately advanced and complex disease of prolonged duration, as well as high rates of diabetes-related complications, obesity, and other comorbid conditions. Other studies in the literature addressing similar issues are based on retrospective analyses of large databases, 19 are limited to academic medical centers, 20 or involve experiments designed to test specifi c treatment interventions, 21 and may have different selection biases than would a primary care practice-based study of unselected patients.
We fi nd that these patients are being treated with 20 There are a number of potential explanations for this suboptimal level of glycemic control in our study patients. While "clinical inertia" and underprescribing of oral hypoglycemic medications and/or insulin may contribute to this problem, [21] [22] [23] [24] it is noteworthy that patients with higher HbA 1c levels were more likely to be on more than 1 oral hypoglycemic agent and/or insulin than were patients whose HbA 1c levels were at or below target. This fi nding may well refl ect the reality that the longer the duration of disease, the more diffi cult it is to maintain glycemic control, and the greater the need for multiple medications, as shown in the UK Prospective Diabetes Study study. 25 Suboptimal patient compliance is another potential explanation; many factors can affect patient compliance, including the patient' s relative utilities or preferences for the short-term discomfort and side effects of treatment compared with the potential long-term benefi ts of decreased morbidity and mortality from diabetic complications.
Even fewer patients achieved the blood pressure and LDL-C target levels. Only 35.3% were at or below target blood pressure recommended by the ADA, with only 74% below the JNC 7 level for stage 1 hypertension (140/90 mm Hg). Only 50.1% of type 2 diabetics in the NHANES III sample had blood pressures below 140/90 mm Hg. 19 In our study, 43.7% of patients achieved LDL-C target levels of 100 mg/dL compared with 15.4% of patients in the NHANES III study 19 and 49.4% of diabetic patients from the Vermont Diabetes Information System Trial. 26 We found that it was even LDL-C = low-density lipoprotein cholesterol Note: Data are expressed as frequencies and percentages (in parentheses); the percentages in the "Row Totals" are row percentages and those in the "Column totals" are column percentages. Data from visit monitoring form.
* Antihypertensive medications for blood pressure control, and lipid-lowering medications for lowdensity lipoprotein cholesterol control. † Totals vary because of missing data.
harder to achieve target levels simultaneously for multiple risk factors. We believe that this fi nding refl ects the enormous complexity involved in controlling multiple risk factors in patients with diabetes. 27 Few patient factors, clinician characteristics, or practice design strategies were associated with the glycemic or cardiovascular risk factor control outcomes. The adverse impact of minority ethnicity status on HbA 1c and LDL-C levels may constitute examples of health disparities in minority populations. The fi nding that more aggressive treatment with diabetic medications was associated with higher HbA 1c values in the multilevel analysis again suggests the possibility that glycemic control becomes more diffi cult with time despite the use of multiple diabetic medications, including insulin. These challenges underline the need for improving the systems that support the care of patients with chronic diseases, 7 including the use of disease registries for tracking patients, 28, 29 along with specifi c clinically important parameters for managing the disease of interest. Only 8.4% of practices in our study reported using registries, suggesting an opportunity for improving active outreach to patients who have not reached target levels of risk factor control. Reengineering is supported by the 2004 Future of Family Medicine Report, 30 which strongly recommended reorganizing primary care practices to provide improved, proactive, patient-centered, population-based chronic care.
The limitations of the study are inherent in practice-based research and cross-sectional descriptive work of this kind. First, the physicians that volunteered to participate may have differed from the larger macrocosm of practicing primary care physicians. Second, we were not able to assess the degree to which the primary care clinicians were able to recruit patients consecutively. Although 52 (55%) clinicians enrolled a minimum of 10 patients, the other clinicians enrolled between 2 and 9. Third, the accuracy of the medical record data cannot be guaranteed. In addition, the laboratory CI = confi dence interval; LDL-C = low-density lipoprotein cholesterol; GED = general equivalency diploma.
Note: In models predicting poor control, an odds ratio that does not include 1.0 is signifi cant at P <.05.
* Estimate signifi cant at P <.05. † Clinician characteristics and practice design features were entered one at a time after all patient characteristics and treatment are in the model.
